Further supporting the notion that disease-initiating breast CSCs are dependent on AKT signaling, treatment with AKT inhibitors suppresses total cell growth, whereas conventional cytostatics impose a selective advantage on BC cells with active SOX2-regulatory elements. This evidence concerns the gene AKT1 and breast cancer.